1	The Bact	terial Profile and Antibiotic Susceptibility Pattern in Respiratory Tract Samples from
2	ART-Exp	erienced HIV-Positive Adults in Uganda.
3		
4	Authors	
5	Lubega (Gloria ^{1*} , Abaasa Andrew ^{1,4} , Willyfred Ochola ¹ , Bernard Kikaire ^{2,3} , Joseph Lutaakome ¹ ,
6	Eugene F	Rugazira ^{1,4} , Yunia Mayanja ^{1,4}
7	1.	Medical Research Council /Uganda Virus Research Institute and London School of
8		Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda
9	2.	Uganda Virus Research Institute, Entebbe, Uganda
10	3.	Department of paediatrics, College of Health Sciences, Makerere University, Kampala,
11		Uganda
12	4.	London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT
13		
14	*Corresp	oonding author:
15	Email: Gl	loria.Lubega@mrcuganda.org (LG)
16		
17		
18		
19		
20		
21		
22		

Abstract

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

Introduction: Microbial infections are a major cause of morbidity and mortality among people living with HIV (PLWH). Respiratory tract infections (RTIs) are responsible for approximately 70% of illnesses among PLWH. Drug resistant bacteria are highly prevalent among PLWH and this is a public health concern. Methods: This is a retrospective analysis of data collected during the COSTOP trial between 2011 and 2013. Sputum collected on spot from participants presenting with a productive cough was examined using Gram, Ziehl-Neelsen stains and cultured on suitable bacteriological media. Antimicrobial sensitivity testing was done on isolated pathogens, by disc diffusion technique. **Results:** We included 687 participants with mean age 41.3 (SD 8.2) years of whom 76.4% were female. Two hundred one sputum samples grew bacteria; Moraxella species (27.4%), Streptococcus pneumoniae(25.4%),Haemophilus influenza(22.4%),Mycobacterium species(4.5%), Pseudomonas species(4.0%), Staphylococcus aureus(4.0%), Escherichia coli (1.0%), Klebsiella species (1.0%), other bacteria (10.4%). A higher monthly income greater than or equal to 30\$ (aOR= 0.63, 95%CI: 0.40-0.99) and longer duration since HIV diagnosis (aOR= 1.06, 95%CI: 1.0-1.11) were found to be independently associated with a positive bacterial culture. Moraxella sp, H. influenza and Pseudomonas had zero sensitivity towards cotrimoxazole. Sensitivity to erythromycin was low among Moraxella sp (28.6%), H. influenza (31.6%) and S. aureus(42.9%) and other bacteria (42.9%). Most isolates were sensitive to Amoxicillin + Clavulanic acid and ceftriaxone.

43 **Conclusion:** There is a very low sensitivity of isolated bacteria to commonly prescribed antibiotics 44 that are more available through the national supply chain, which is of public health concern. 45 Urgent steps to tackle the high antimicrobial resistance among PLWH is required. 46 47 Keywords: PLWH, Bacteria, Antimicrobial Susceptibility, Antibiotic, Respiratory tract Infection 48 49 **Abbreviations** 50 API – Analytical profile index 51 AMR – Antimicrobial Resistance 52 ART - Antiretroviral therapy 53 CD4 - Cluster of Differentiation 4 54 COSTOP - Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults in 55 Uganda: a randomised controlled trial 56 **EUCAST - European Committee on Antimicrobial Susceptibility Testing** 57 HIV - Human Immune Deficiency Virus 58 PLWH - People living with HIV 59 RTIs – Respiratory tract infections 60 SSA - Sub-Saharan Africa 61 62

Introduction

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

For over three decades, Human Immunodeficiency Virus (HIV) infection remains a disease of public health importance with approximately 37.6 million people living with HIV (PLWH) globally in 2020 (1). Sub-Saharan Africa (SSA) suffers the highest burden of HIV with nearly 70% of global HIV infections (2). Since the introduction of antiretroviral therapy (ART), PLWH have an improved quality of life however, microbial infections are still a major cause of morbidity and mortality among this population (3), with approximately 70% of illnesses being respiratory tract infections (RTIs) (4, 5). Ojha et al. reported a high prevalence (47%) of respiratory tract infections caused by bacterial pathogens among PLWH(5) and, factors associated with these infections include low CD4 counts ($<200 \text{ cells/}\mu$ l) and detectable viral loads (5, 6). HIV infection causes a progressive depletion of CD4 T cells as well as an impairment of cellular and humoral immunity through a dysfunction of the T and B cells respectively (7). A dysfunction of T cells leads to abnormal cellular responses while a dysfunction of B cells leads to a lack of antibody responses to infections. The resultant immune dysfunction, deregulation and depletion of CD4 lymphocytes causes an increased susceptibility to infections and the subsequent risk of other complications like resistant pathogens (8, 9). HIV infection causes an alteration in lung host defences for example, it affects mucociliary function which may contribute to an increase RTIs among PLWH (9). PLWH are at increased risk of hospital acquired infections due to their frequent contact with health care system through frequent clinic visits and admissions (10). The frequent infections and admissions among PLWH, pill burden leading to unfinished doses and inappropriate use of drugs through self-medication are some of the factors that have led to the development of antimicrobial resistance among this population (11).

Antimicrobial resistance is an emerging global problem of public health importance (4). Previous studies have reported a much higher prevalence of drug resistant bacteria among PLWH (79%) compared to their HIV negative counterparts (30%) (10, 12). Prophylactic cotrimoxazole given to PLWH over prolonged periods of time to prevent opportunistic infections has been reported to give rise to antibiotic resistance (13). Resistant microbes are more difficult to manage since they require alternative medications and or higher doses of drugs, both of which are more expensive, not readily available in SSA and or toxic to the patient (13). Additionally, laboratory capacity for identifying AMR is still limited in many parts of SSA; data are therefore still limited on antimicrobial susceptibility patterns among PLWH in SSA (10). (10). It is important to understand the common disease-causing pathogens among PLWH and current antibiotic susceptibility patterns for better management. We studied the susceptibility pattern of microorganisms isolated from respiratory samples taken from PLWH in central Uganda.

Methods

Study design, setting: We conducted a retrospective analysis of data collected during the COSTOP trial (Safety of discontinuing cotrimoxazole prophylaxis among HIV infected adults in Uganda: a randomised controlled trial, ISRCTN44723643) conducted between January 2011 and March 2013 in two HIV care clinics in Masaka and Entebbe in central Uganda. (14, 15).

The COSTOP trial enrolled HIV positive adults (≥18 years) who had been on ART and cotrimoxazole prophylaxis for at least six months, clinically asymptomatic and had CD4 cell counts of >250 cells/mm³ prior to enrolment. Individuals who had an acute illness, grade three

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

or four anaemia, neutropenia or thrombocytopenia, known hypersensitivity to cotrimoxazole, and pregnant women were excluded. **Participants and Eligibility** The current analysis included COSTOP trial participants who presented to the clinic with a productive cough and provided sputum at any time during the trial. Participants were asked to collect sputum in a dry, leak proof, sterile container after rinsing their mouth with water. Samples were immediately transported to the laboratory for microscopy, culture, and sensitivity. Laboratory: Samples were examined microscopically using Gram, Ziehl-Neelsen stains and cultured on suitable bacteriological media (Blood, Chocolate, MacConkey agar and Subouroid agar). Samples were incubated at 37°c for 24hrs, the pathogens that grew from incubated samples were identified microscopically and biochemically using analytical profile index (API) and by sensitivity testing. Antimicrobial sensitivity testing was done on isolated pathogens, by disc diffusion technique(16). The diameter of the zone of inhibition was measured and compared to that of European Committee on Antimicrobial Susceptibility Testing (EUCAST) standards(17) to determine resistance or sensitivity of a pathogen to the antimicrobial. Study variables The dependent variable was bacterial culture positivity of sputum collected during the study. The independent variables were gender, age (years) categorized under age groups <35years, 35-55 years and >55 years, recent and initial CD4 counts categorized into <200, 200-300 and >300 cells/ul, study arm in the COSTOP trial (cotrimoxazole arm, placebo arm), highest education level attained categorized into none, primary and secondary school, marital status categorized into married, divorced and single, monthly income (\$) categorized into those earning <30 and >/=30,

ART regimen categorized into First line and second line, duration on ART (years) and period since HIV diagnosis (years). Statistical analysis: The data collected were managed in MS Access, 2003 (Microsoft Corporation, Redmond, WA) and data analyses were performed using Stata 14 (Stata Corp, College Station, Texas 77845 USA) [11]. Continuous variables were presented as means with standard deviation (SD) and categorical variables as frequencies and percentages. The proportion of bacterial culture positivity overall, and by different participant characteristics were determined as number culture positive divided by the total sample, expressed as a percentage. A bar graph was used to display the frequency of bacterial isolates, and frequency and percentages used to summarise antibacterial susceptibility of bacteria isolated in sputum. To determine factors associated with bacterial culture positivity, we fitted both univariable and multivariable logistic regression models. At univariable analysis, all factors in logit models with likelihood ratio test p-value <0.2, were selected for multivariable logit model. Factors were retained in the multivariable logit model if their inclusion did not make the model fit significantly worse at p<0.05 on likelihood ratio test. We present the results as adjusted odds ratios (AOR) with corresponding 95% confidence intervals (CI)

Results

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

Participants' characteristics

We included 687 participants in the analysis with mean age was 41.3 years (SD ± 8.23) and 76.4% were female. Overall, 51.1% of participants received cotrimoxazole, 70.2% earned less than \$30 monthly and 60.3% had primary level education. We observed that the mean period since HIV

diagnosis was 5.49 years (SD \pm 4.50) and the mean period on ART was 3.79 years (SD \pm 1.86) with 97.9% of participants on a first line ART regimen. Regarding CD4 counts, 89.7% had a recent CD4 of >300cell/µl however, 68.4% had a nadir CD4 count of <200cell/µl (Table 1).

152**Table 1:** Factors associated with bacterial growth in sputum cultures among ART-experienced HIV-153 positive individuals in Uganda (N=687)

Characteristic	N =687 Culture positive n(%) (%)		OR (95% CI)	P-value	AOR (95% CI)	P-value	
Sex							
Female	525 (76.4)	113 (21.5)	1		1		
Male	162 (23.6)	43 (26.5)	1.32 (0.88-1.98)	0.183	1.37 (0.89-2.11)	0.156	
Age (years)							
<35	161 (23.4)	40 (24.8)	1				
35-55	482 (70.2)	110 (22.8)	0.89 (0.59-1.36)	0.599	0.91 (0.59-1.41)	0.666	
>55	44 (6.4)	6 (13.6)	0.48 (0.19-1.21)	0.120	0.43 (0.17-1.13)	0.086	
Receiving cotrimoxazole							
cotrimoxazole	351 (51.1)	71 (20.2)	1				
placebo	336 (48.9)	85 (25.3)	1.34 (0.93-1.91)	0.113	1.37 (0.94-1.98)	0.098	
Education level							
None	101 (14.7)	26 (25.7)	1				
Primary	414 (60.3)	91 (22.0)	0.81 (0.49-1.34)	0.419			
Secondary	172 (25.0)	39 (22.7)	0.85 (0.48-1.50)	0.566			
Marital status							
Married	284 (41.3)	62 (21.8)	1				
Divorced	377 (54.9)	88 (23.3)	1.09 (0.75-1.58)	0.646			
Single	26 (3.8)	06 (23.1)	1.07 (0.41-2.79)	0.883			
Monthly income (\$)							
<30	448 (70.2)	109 (24.3)	1				
>/=30	190 (29.8)	38 (20.0)	0.78 (0.51-1.18)	0.236	0.63 (0.40-0.99)	0.049	
Recent CD4*							
<200	11 (1.6)	1 (9.1)	1				
200-300	58 (8.4)	18 (31.0)	4.50 (0.53-37.85)	0.166	5.09 (0.58-44.60)	0.141	
>300	616 (89.7)	137 (22.2)	2.86 (0.36-22.54)	0.318	2.86 (0.35-23.44)	0.326	
Nadir CD4*							
<200	470 (68.4)	105 (22.3)	1				
200-300	123 (17.9)	30 (24.4)	1.12 (0.70-1.79)	0.629			
>300	18 (2.6)	4 (22.2)	0.99 (0.32-3.08)	0.991			
ART regimen*							
First line	662 (97.9)	151 (22.8)	1				
Second line	14 (2.1)	1 (7.1)	0.26 (0.03-201)	0.196	0.24 (0.03-1.94)	0.180	

Duration on ART, (mean (SD)) yrs	3.79 (1.86)	3.75 (1.84)	0.98 (0.89-1.08)	0.726		
Years since HIV						
diagnosis, (mean (SD))	5.49 (4.50)	6.20 (6.83)	1.04 (1.00-1.09)	0.053	1.06 (1.01-1.11)	0.025
vrs						

¹⁵⁴ ART = antiretroviral therapy; HIV = Human Immunodeficiency Virus

Bacterial culture positivity and prevalence of isolated microorganisms

A total of 201 (29.3%) samples had bacterial growth, with 9 samples growing more than one bacterial organism. Isolated bacteria included *Moraxella species* (55, 27.4%), *Streptococcus pneumoniae* (51, 25.4%), *Haemophilus influenza* (45, 22.4%), *Mycobacterium species* (11, 4.5%), *Pseudomonas species* (8, 4.0%), *Staphylococcus aureus* (8, 4.0%), *Escherichia coli* (2, 1.0%), *Klebsiella species* (2, 1.0%) and other bacteria (19, 10.4%) (Figure 1).

Factors associated with bacterial culture positivity

The factors found to be independently associated with having a bacterial culture positive sample where; monthly income \geq \$30 (aOR= 0.63, 95%CI 0.40-0.99) compared to those earning below \$30 and longer duration of years since HIV diagnosis [aOR= 1.06, 95% CI 1.01-1.11]. Participants who received placebo were more likely to have a positive sputum culture than those who received cotrimoxazole however this was not found to have statistical significance (aOR= 1.37, 95% CI 0.94-1.98) (Table 1).

Antibiotic sensitivity of isolated microorganisms

The sensitivity of bacterial isolates is shown in Table 2. Most isolates were highly sensitive to Amoxicillin + Clavulanic acid and ceftriaxone with *Moraxella sp. and, Streptococcus pneumoniae* having 100% sensitivity to both. *Pseudomonas* had 100% sensitivity to gentamycin while H. *influenza* showed 100% sensitivity to ceftriaxone and 88.6% sensitivity to Amoxicillin + Clavulanic acid. Other bacteria showed the highest sensitivity to ceftriaxone and gentamycin (85.7%).

All isolates had very low sensitivity to cotrimoxazole (<16.7%). *Moraxella sp*, H. *influenza* and *Pseudomonas* showed zero sensitivity to cotrimoxazole. *Moraxella sp* (28.8%), H. *influenza* (31.6%), S. *aureus* (42.9%) and other bacteria (42.9%) also had low sensitivity towards erythromycin. H. *influenza* (50.0%) and other bacteria (69.2%) had relatively low sensitivity towards ciprofloxacin.

Table 2: Antibacterial susceptibility rates of bacterial isolated from sputum of PLWH.

	Moraxella species		Streptococcus pneumoniae		Haemophilus influenza		Pseudomonas species		Staphylococcus aureus			Others						
	N=55		N=51		N=45		N=8		N=8			N=34						
	Т	S	S %	Т	S	S %	Т	S	S %	Т	S	S %	Т	S	S %	Т	S	S %
Cotrimoxazole	43	0	0.0	39	1	2.6	37	0	0.0	3	0	0.0	6	1	16.7	21	2	9.5
Erythromycin	42	12	28.6	38	30	78.9	38	12	31.6	0	0	n/a	7	3	42.9	7	3	42.9
Amoxyl+clavulanic acid	42	42	100.0	4	4	100.0	35	31	88.6	0	0	n/a	6	6	100.0	7	6	85.7
ciprofloxacin	0	n/a	n/a	0	n/a	n/a	2	1	50.0	5	4	80.0	0	n/a	n/a	13	9	69.2
Ceftriaxone	2	2	100.0	35	35	100.0	1	1	100.0	2	1	50.0	0	n/a	n/a	13	10	76.9
Gentamycin	0	n/a	n/a	0	n/a	n/a	0	0	n/a	5	5	100.0	0	n/a	n/a	14	12	85.7

NOTE: Amoxyl + clavulanic acid = Amoxicillin + Clavulanic acid, T = number tested, S = sensitivity

Discussion

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

We cultured sputum from ART experienced PLWH with a productive cough and approximately 30% of the sputum samples had bacterial growth. This is similar to what was reported by Akingbade OA et al who found a prevalence of 24.2% positive cultures from sputum collected from participants with lower RTIs (18), but lower than approximately 44% prevalence reported by Adhanom et al (19). Adhanom et al included both ART experienced and ART naïve participants that were suspected of pneumonia, which more a severe disease than the presentation of cough that was considered in our study. Our participants were all ART experienced, indicating they might have had a better immunity than those included in Adhanom et al study. Additionally, Adhanoum et al's study was conducted in three years after the COSTOP study, during which period there might have been an increase in antimicrobial resistance, leading to reduced response by the bacteria to antibiotics hence increased bacterial growth on culture. We found a high prevalence of Moraxella species (28%) in our sputum samples. Moraxella species is usually normal flora of the respiratory tract, however, previous studies have reported Moraxella as a pathogen of the lower respiratory tract in immunosuppressed patients (20). Abdullah et al reported a relatively high prevalence of Moraxella in patients with lower RTIs among the elderly and immunosuppressed (20). Our finding of high proportion of participants with Moraxella species may indicate a less than complete immune recovery in these patients. The Moraxella species isolated in our study was sensitive to amoxicillin+ clavulanic acid and ceftriaxone and had very low sensitivity to erythromycin and cotrimoxazole, which is similar to what Abdullah et al reported (20). The very low sensitivity of all the bacterial isolates to

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

cotrimoxazole is not surprising since our study participants were either on active cotrimoxazole prophylaxis, or had previously used cotrimoxazole prophylaxis. HIV infection leads to a low CD4 count and a defective immune system which renders people infected with the HIV virus susceptible to microbial infections leading to a greater use of antibiotics among people living with HIV. The increased use of antibiotics may explain the observed low sensitivity of isolated bacteria to cotrimoxazole (21), and erythromycin (20) among PLWH in this study and other studies. Participants that received placebo were more likely to have a positive sputum culture compared to those receiving cotrimoxazole, however this was not statistically significant. This implies that use of Cotrimoxazole did not provide protection against respiratory infections in this study population. This could be due to the fact that the study participants were ART experienced, had improved and stabilised immunity, and thus were no longer susceptible to infections associated with compromised immunity. Although the study was not powered to answer the question on the effect of cotrimoxazole on respiratory bacterial infections, this finding supports the 2020 Uganda HIV prevention and treatment guidelines that recommends use of prophylactic cotrimoxazole only in adults with advanced HIV disease, those newly diagnosed with HIV, children below 18 years, pregnant and breastfeeding women (22). An association of long term use of cotrimoxazole among PLWH with an increase in resistance to cotrimoxazole has been reported in previous studies (23, 24) therefore, reduced use of cotrimoxazole in this population may reduce resistance of microbes to it. The participants in the study were generally low earners as majority of them were earning less than \$30 a month. Participants who earned more than \$30 were less likely to have positive

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

Acknowledgements

bacterial cultures compared to those who earned less than \$30. This is similar to evidence that suggests that those with lower socio-economic status are more vulnerable, have higher burden of disease and thus more prone to frequent respiratory infections (25). Participants who had a longer duration since HIV diagnosis were more likely to have a positive bacterial culture. This finding requires further investigation since there is no clear biological explanation between duration of HIV infection and risk of bacterial infections. **Strengths and Limitations** This study among ART experienced participants has applicable results as majority of PLWH are on ART following the test and treat policy. Previous studies have mainly reported antimicrobial sensitivity among ART naïve patients. The study was however, a secondary data analysis and this limited the number of antimicrobial drugs that could have been tested for bacterial sensitivity. We could also not explore other factors for example viral load, that could be associated with a positive sputum culture. **Conclusion** High prevalence of bacterial isolates with most being susceptible to Amoxicillin + Clavulanic acid and ceftriaxone. However, majority of organisms showed very low sensitivity to cotrimoxazole and erythromycin that are cheaper and readily available. As antibiotic choices are becoming limited due to low sensitivity of microbes to these drugs, there is an urgent need to invest in the prevention and control of increasing antibiotic resistance.

245 We would like to acknowledge the contributions of the COSTOP trial team and the contribution 246 of the study participants 247 **Competing interests** 248 The authors declare no competing interests. 249 **Ethical approval statement** 250 All participants enrolled into the main COSTOP trial gave written informed consent prior to any 251 study procedures. The COSTOP study received approval from Uganda Virus Research Institute 252 Ethics committee, National Drug Authority and Uganda National Council for Science and 253 Technology. 254 **Author Contributions:** 255 LG conceived and designed the study, participated in data collection, analysis and interpretation, 256 AA contributed to data analysis. All authors read, revised the original manuscript and approved 257 the final version of manuscript. 258 259 References 260 UNAIDS. Global HIV & AIDS statistics - Fact sheet 2021 [Available from: 261 https://www.unaids.org/en/resources/fact-262 sheet#:~:text=GLOBAL%20HIV%20STATISTICS,AIDS%2Drelated%20illnesses%20in%202020. 263 Barankanira E, Molinari N, Niyongabo T, Laurent C. Spatial analysis of HIV infection and 264 associated individual characteristics in Burundi: indications for effective prevention. BMC Public Health. 265 2016;16(1):118. 266 Ford N, Shubber Z, Meintjes G, Grinsztejn B, Eholie S, Mills EJ, et al. Causes of hospital admission 267 among people living with HIV worldwide: a systematic review and meta-analysis. The lancet HIV. 268 2015;2(10):e438-44. 269 Gauchan P, Lekhak B, Sherchand JB. The prevalence of lower respiratory tract infection in adults 4. 270 visiting Tribhuvan University Teaching Hospital. Journal of Institute of Medicine Nepal. 2007;28(2):10-4. 271 Ojha CR, Rijal N, Khagendra KC, Palpasa K, Kansakar P, Gupta BP, et al. Lower respiratory tract 272 infections among HIV positive and control group in Nepal. VirusDisease. 2015;26(1):77-81.

- 273 6. Lamas CC, Coelho LE, Grinsztejn BJ, Veloso VG. Community-acquired lower respiratory tract
- infections in HIV-infected patients on antiretroviral therapy: predictors in a contemporary cohort study.
- 275 Infection. 2017;45(6):801-9.
- 7. Cairns G. HIV damages B-cells as well as T-cells: new treatment targets identified NAM-
- aidsmap2011 [Available from: https://www.aidsmap.com/news/jun-2011/hiv-damages-b-cells-well-t-277
- 278 <u>cells-new-treatment-targets-identified</u>.
- 279 8. Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013;254(1):54-64.
- 281 9. Crothers K, Huang L, Goulet JL, Goetz MB, Brown ST, Rodriguez-Barradas MC, et al. HIV infection
- and risk for incident pulmonary diseases in the combination antiretroviral therapy era. American journal of respiratory and critical care medicine. 2011;183(3):388-95.
- Olaru ID, Tacconelli E, Yeung S, Ferrand RA, Stabler RA, Hopkins H, et al. The association
- between antimicrobial resistance and HIV infection: a systematic review and meta-analysis. Clinical
- microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2021;27(6):846-53.
- 288 11. Rameshkumar MR, NarasingamArunagirinathan, editors. Drug-Resistant Bacterial Infections in HIV Patients 2018.
- 290 12. Marbou WJT, Kuete V. Bacterial resistance and immunological profiles in HIV-infected and non-
- infected patients at Mbouda AD LUCEM Hospital in Cameroon. Journal of Infection and Public Health.
- 292 2017;10(3):269-76.
- 293 13. Arunagirinathan MRRaN. Drug-Resistant Bacterial Infections in HIV Patients, Advances in HIV
- and AIDS Control. IntechOpen. 2018.
- 295 14. Anywaine Z, Abaasa A, Levin J, Kasirye R, Kamali A, Grosskurth H, et al. Safety of discontinuing
- cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP
- trial): Design. Contemporary clinical trials. 2015;43:100-4.
- 298 15. Anywaine Z, Levin J, Kasirye R, Lutaakome JK, Abaasa A, Nunn A, et al. Discontinuing
- $299 \qquad \hbox{cotrimoxazole preventive the rapy in HIV-infected adults who are stable on antiretroviral treatment in} \\$
- 300 Uganda (COSTOP): A randomised placebo controlled trial. PloS one. 2018;13(12):e0206907.
- 301 16. Novick Jr WJ. Development of in vitro susceptibility testing criteria and quality control
- 302 parameters. Elsevier; 1989. p. 60-2.
- 17. Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, et al. EUCAST expert rules in
- antimicrobial susceptibility testing. Clinical Microbiology and Infection. 2013;19(2):141-60.
- 305 18. A A, Ogiogwa J, Okerentugba P, Innocent-Adiele C, Onoh C, Nwanze J, et al. Prevalence of
- 306 Antibiotic Susceptibility Pattern of bacterial Agents Involve In lower Respiratory Tract Infection in
- 307 Abeokuta ,Ogun State ,Nigeria. Report and Opinion. 2012.
- 308 19. Adhanom G, Gebreegziabiher D, Weldu Y, Gebreyesus Wasihun A, Araya T, Legese H, et al.
- 309 Species, Risk Factors, and Antimicrobial Susceptibility Profiles of Bacterial Isolates from HIV-Infected
- Patients Suspected to Have Pneumonia in Mekelle Zone, Tigray, Northern Ethiopia. BioMed Research
- 311 International. 2019;2019:8768439.
- 312 20. Abdullah FE, Ahuja KR, Kumar H. Prevalence and emerging resistance of Moraxella catarrhalis in
- 313 lower respiratory tract infections in Karachi. JPMA The Journal of the Pakistan Medical Association.
- 314 2013;63(11):1342-4.
- 315 21. Oguche JI-o, Bolaji RO, Onaolapo JA, Abah SE, Kwaghe VG, Akor SE, et al. BACTERIAL INFECTION
- 316 AND ANTIBIOTIC RESISTANCE IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS PRESENTING
- 317 LOWER RESPIRATORY TRACT INFECTION IN NIGERIA. medRxiv. 2021:2021.09.05.21263138.
- 318 22. Health Mo. CONSOLIDATED GUIDELINES FOR THE PREVENTION AND TREATMENT OF HIV AND
- 319 AIDS IN UGANDA 2020 [Available from:

- 320 https://differentiatedservicedelivery.org/Portals/0/adam/Content/HvpzRP5yUUSdpCe2m0KMdQ/File/U
- 321 ganda Consolidated%20HIV%20and%20AIDS%20Guidelines%202020%20June%2030th.pdf.
- 322 23. Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK, Gerberding JL. Emergence of
- 323 trimethoprim-sulfamethoxazole resistance in the AIDS era. The Journal of infectious diseases.
- 324 1999;180(6):1809-18.
- 325 24. Zachariah R, Harries AD, Spielmann MP, Arendt V, Nchingula D, Mwenda R, et al. Changes in
- 326 Escherichia coli resistance to co-trimoxazole in tuberculosis patients and in relation to co-trimoxazole
- prophylaxis in Thyolo, Malawi. Malawi medical journal: the journal of Medical Association of Malawi.
- 328 2002;14(2):10-2.

- 329 25. Kiwanuka SN, Ekirapa EK, Peterson S, Okui O, Rahman MH, Peters D, et al. Access to and
- utilisation of health services for the poor in Uganda: a systematic review of available evidence.
- Transactions of the Royal Society of Tropical Medicine and Hygiene. 2008;102(11):1067-74.




Fig. 1 Frequency of bacterial isolates. Figure